Samsung Bioepis Co., Ltd.
Samsung Bioepis Co., Ltd.
Explore linked clinical trials.5 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Trial to Investigate the Safety of E303 in Participants With Advanced Refractory Solid Tumors | Advanced Solid Tumors | Recruiting | Phase 1 | 2026-10-01 | NCT07524348 | |
| A Trial to Evaluate the Safety and Usability of the SB15 PFS in Trial Participants With AMD, Macular Oedema Secondary to RVO, or Diabetic Macular Oedema | Diabetic Macular Oedema; Macular Oedema Secondary to RVO; Neovascular Age-related Macular Degeneration | Active, not recruiting | Phase 2 | 2026-09-28 | NCT07844343 | |
| A Study to Compare the Pharmacokinetics, Safety, Tolerability, and Immunogenicity of SB35 (Proposed Ixekizumab Biosimilar) to Taltz in Healthy Participants | Healthy | Not yet recruiting | Phase 1 | 2026-08-27 | NCT07789964 | |
| A Study to Compare the Efficacy, Safety, Pharmacokinetics, and Immunogenicity Between SB27 and Keytruda in Subjects With Metastatic Non-squamous Non-small Cell Lung Cancer | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Active, not recruiting | Phase 3 | 2026-07-07 | NCT06348199 | |
| A Study to Compare the Pharmacokinetics, Efficacy, Safety, and Immunogenicity of Pembrolizumab (SB27, EU Sourced Keytruda, and US Sourced Keytruda) in Subjects With Stage II-IIIA NSCLC Following Complete Resection and Adjuvant Platinum-based Chemotherapy | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Active, not recruiting | Phase 1 | 2026-05-05 | NCT06268613 |